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Edited by Karen FlemingThe conserved C-terminal end segment of troponin I (TnI)
plays a critical role in regulating muscle relaxation. This
function is retained in the isolated C-terminal 27 amino acid
peptide (residues 184–210) of human cardiac TnI (HcTnI-C27):
When added to skinned muscle fibers, HcTnI-C27 reduces the
Ca2+-sensitivity of activated myofibrils and facilitates relaxa-
tion without decreasing the maximum force production.
However, the underlying mechanism of HcTnI-C27 function is
unknown. We studied the conformational preferences of
HcTnI-C27 and a myopathic mutant, Arg192His, (HcTnI-C27-
H). Both peptides were mainly disordered in aqueous solution
with a nascent helix involving residues from Trp191 to Ile195,
as shown by NMR analysis and molecular dynamics simula-
tions. The population of nascent helix was smaller in HcTnI-
C27-H than in HcTnI-C27, as shown by circular dichroism
(CD) titrations. Fluorescence and isothermal titration calo-
rimetry (ITC) showed that both peptides bound tropomyosin
(αTm), with a detectably higher affinity (10 μM) of HcTnI-
C27 than that of HcTnI-C27-H (15 μM), consistent with an
impaired Ca2+-desensitization effect of the mutant peptide on
skinned muscle strips. Upon binding to αTm, HcTnI-C27 ac-
quired a weakly stable helix-like conformation involving resi-
dues near Trp191, as shown by transferred nuclear Overhauser
effect spectroscopy and hydrogen/deuterium exchange
experiments. With the potent Ca2+-desensitization effect of
HcTnI-C27 on skinned cardiac muscle from a mouse model of
hypertrophic cardiomyopathy, the data support that the
C-terminal end domain of TnI can function as an isolated
peptide with the intrinsic capacity of binding tropomyosin,
providing a promising therapeutic approach to selectively
improve diastolic function of the heart.This article contains supporting information.
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© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The contraction and relaxation of striated muscles, i.e.,
cardiac and skeletal muscles, are regulated by Ca2+ via the
troponin complex in sarcomeric myofilaments. Troponin
consists of three protein subunits: the Ca2+-binding subunit
troponin C (TnC), the inhibitory subunit troponin I (TnI), and
the tropomyosin (Tm)-binding subunit troponin T (TnT)
(1–4). Muscle contraction results from a rise of cytosolic Ca2+
that binds TnC to induce allosteric changes in TnC, TnI, TnT,
and Tm, which allows the myosin heads to form strong cross-
bridges with actin filament to activate myosin ATPase and
generate power strokes and the shortening of sarcomeres (5).
Downstream of the Ca2+-receptor TnC, TnI acts as an
allosteric signal transducer to regulate myofilament activity
critical to muscle relaxation. Vertebrate TnI has diverged into
three muscle-type isoforms (3) with largely conserved struc-
tures where the C-terminal end segment is the most conserved
with a very high degree of sequence similarity among muscle
type isoforms and across species (6) (Fig. 1). X-ray crystal-
lography studies determined the folded structure of partial
troponin complex containing whole TnC, most part of TnI,
and a small portion of TnT (7, 8). The C-terminal end 27
residues of TnI (C27) were not resolved in the crystal struc-
tures, indicating a high mobility.
The C27 segment of cardiac TnI is critical to cardiac
function (9). Mutation in this segment impairs cardiac muscle
relaxation (10). We have previously shown that it is a Ca2+-
regulated exposed allosteric structure in reconstituted
troponin complex and binds tropomyosin at low Ca2+-state,
indicating a role in the inhibitory function of TnI during
muscle relaxation (11). Independent of the TnI backbone,
isolated C27 peptide folds into a native conformation recog-
nized by an anti-TnI C-terminus monoclonal antibody (mAb)
TnI-1 (6) in physiological solution and retains binding affinity
for Tm (12). The mAb TnI-1 recognized epitope in the C-
terminal end peptide of TnI is conserved in all vertebrate TnI
sequenced to date. A restrictive cardiomyopathy mutation
(Arg192His) in the C-terminal end segment of cardiac TnI (13)
diminishes the bindings to mAb TnI-1 and Tm (12).J. Biol. Chem. (2021) 296 100228 1
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Figure 1. The highly conserved C-terminal peptide of TnI. A, linear structures of the three isoforms of human TnI are aligned to show their exon or-
ganizations, major functional sites, and the location of the mAb TnI-1 epitope. The regions resolved in the crystal structure of human cardiac and chicken
fast skeletal muscle troponin are shaded. The highly conserved amino acid sequences of the exon 8-encoded C-terminal end segment of cardiac (cTnI), slow
skeletal muscle, and fast skeletal muscle isoforms from representative vertebrate species are shown by the alignment. The restrictive cardiomyopathy
mutation, Arg192His, is shown in bold. B, the amino acid sequence of HcTnI-C27 is outlined with the residues numbered according to their position in intact
human cardiac TnI. The residues in bold are those labeled with 13C and 15N in this study.
Structure and function of C-terminal peptide of troponin IWhen added to skinned cardiac muscle strips, the C27
peptide of human cardiac TnI (HcTnI-C27) causes reduction
of myofilament Ca2+-sensitivity especially at the activated state
without decreasing the maximum force production (12). The
data indicate that the C-terminal end segment of TnI is a
regulatory element of troponin, which retains the native
configuration and physiological effect on myofilament Ca2+-
desensitization in the form of free peptide. Without negative
inotropic impact, this short peptide may be developed into a
novel reagent to selectively facilitate the relaxation of activated
cardiac muscle for the treatment of diastolic dysfunction and
heart failure.
To establish the underlying mechanism, it is necessary to
understand how free HcTnI-C27 peptide folds into functional
structure. In the present study, we examined the conforma-
tional preferences of isolated HcTnI-C27 peptide in solution
and the restrictive cardiomyopathic mutant HcTnI-C27-H
(Arg192His) by using a combination of experimental and
MD simulation approaches. The results demonstrate that both
peptides populated a nascent-helix conformation, of which the
amount of helical conformation was reduced in the mutant
peptide that exhibits impaired physiological effect on Ca2+-
sensitivity and contractility of cardiac muscle. HcTnI-C27
binds αTm with low-micromolar affinity, acquiring a
helix-like conformation. With HcTnI-C27’s potent Ca2+-
desensitization effect on skinned cardiac muscle from a mouse
model of hypertrophic cardiomyopathy, the data support that
the C-terminal end domain of TnI can function in the form of2 J. Biol. Chem. (2021) 296 100228isolated peptide to modify muscle contractility as a potential
therapeutic reagent to improve diastolic function for the
treatment of heart failure.Results
HcTnI-C27 and HcTnI-C27-H peptides are monomers in
physiological buffer and populate a nascent helix
We first determined the tendency of HcTnI-C27 and
HcTnI-C27-H peptides to self-associate by measuring the
translational diffusion coefficient, D. Both peptides showed
predicted Rh values comparable with those theoretically
calculated for random-coil peptides (14) with the same mo-
lecular weight, suggesting that both peptides were monomeric
and mainly disordered in the physiological buffer condition at
the concentration tested (100 μM) (Table 1).
The far-UV CD spectra of HcTnI-C27 and HcTnI-C27-H
peptides in aqueous solution both showed an intense band at
200 nm with a small shoulder at 222 nm, suggesting that they
were mainly disordered (Fig. 2A). The presence of the 222 nm
shoulder could be due to a population of turn- or helix-like
structures and/or the existence of aromatic residues in the
peptides (Trp191 and Phe208 in HcTnI-C27; and Trp191,
His192, and Phe208 in HcTnI-C27-H), which also absorb at
222 nm (15, 16). While the possible interference of those
residues is considered, the amount of helical structure in both
peptides was estimated from the CD spectra by using two
methods as follows.
Table 1
Hydrodynamic properties of the C27 peptides (at pH 7.2 and 10 C)
Peptide D (cm2 s−1) × 106 (Rh, Å)
a Rh, Å
b Molecular weight (Da)
HcTnI-C27 9.9 ± 0.1 (13.3 ± 0.3) 15 ± 4 3180.55
HcTnI-C27-H 10.1 ± 0.3 (13.0 ± 0.4) 15 ± 4 3161.50
a Errors are uncertainties to Equation 2. The Rh values were obtained by comparison with the Rh of dioxane (2.12 Å).
b Calculated from the scale law: Rh = (0.027 ± 0.01) MW
(0.50 ± 0.01) (14).
Structure and function of C-terminal peptide of troponin IFirst, from the molar ellipticity at 222 nm, [Θ]222, we esti-
mated the percentage of helical structure for the peptides
assuming that the value of [Θ]222 for a fully formed helix
is −39,500 deg cm2 dmol−1 (17). The estimated values were
6.7% (−2669.8 deg cm2 dmol−1) for HcTnI-C27 and 4.6%
(−1829.7 deg cm2 dmol−1) for HcTnI-C27-H (Fig. 2A). Spectral
deconvolution using the DICHROWEB web page (18, 19)
yielded a prediction of a very small population of helical
structure in both peptides: 0.5% to 10%, depending on the
algorithm used, for HcTnI-C27, and 0.4% to 6% for HcTnI-
C27-H. Considering the possible interference of aromatic
residues indicated above, these differences in the deconvolu-
tion of the spectra of both peptides, or in the helix estimation
from the ellipticity at 222 nm, are taken with caution. And
second, TFE titrations followed by CD were employed to es-
timate the equilibrium constant (K) for the disordered ↔ he-
lical reaction (20, 21), assuming that there were no
intermediates (as suggested by the presence of an isodichroic
wavelength for each peptide titration). Unlike the above ana-
lyses, which make assumptions about how the ellipticity signal
at 222 nm relates to secondary structure content, TFE titration
allows the determination of helical content derived from the
free-energy change of such equilibrium. The [Θ]222 increased
in absolute value for both peptides as TFE concentration was
raised (Fig. 2B). The titration for HcTnI-C27 was more
cooperative than that for HcTnI-C27-H, with m-values of 42 ±
14 kcal/(mol %) and 117 ± 20 kcal/(mol %), respectively.
However, the [TFE]1/2 (the midpoint of the transition in % (v/
v)) did not differ significantly: 16 ± 8% for wild-type and 23 ±
2% for the mutant (Fig. 2B). These values yielded a 7.5% of
helical population for HcTnI-C27 (K = 0.0818) and 1% for the
mutant (K = 0.012). These findings suggested that the ten-
dency to populate an α-helical structure was larger in the wild-
type peptide.
Additionally, we used AGADIR (22–27) to have a theoret-
ical estimate of the helical population of both peptides.
AGADIR is widely used to qualitatively predict the helical
behavior of peptides by CD, mimicking residue-level helical
tendency of peptides in NMR (24–27). The predictions (at 10
C and pH 7.2) yielded very small percentages of helical
structure (Fig. 2C) for both peptides: 1.43% for HcTnI-C27 and
0.82% for HcTnI-C27-H. It is important to note that these
values indicate that the percentage of helical structure in both
peptides was small as anticipated for short 27-residue-long
peptides. However, the change of only one amino acid in the
mutant produced notable difference in helicity (Fig. 2C).
Therefore, the far-UV CD data indicate that both peptides
weakly populated helix-like conformations, and suchpopulation was slightly higher in the wild-type peptide than in
the myopathic mutant.
Amino acid residues involved in the nascent helix of HcTnI-
C27 and HcTnI-C27-H peptides
We carried out homonuclear 2D-1H-NMR experiments to
determine the presence of the helix-like conformations. The
peptides were mainly disordered in aqueous solution, but there
were residual conformations as shown by two pieces of evi-
dence. First, no long- or medium-range NOEs were detected
(Fig. 3), but sequential NN(i, i + 1) NOEs (and ROEs) were
observed for residues around Trp191 and Ile195 in the HcTnI-
C27 peptide (Fig. 3A), with most of these NOEs not being
present in HcTnI-C27-H (Fig. 3B). These contacts indicate the
presence of a nascent helix, although it was not very stable, as
shown by the absence of protected amide protons of the
peptides in the presence of D2O (hydrogen/exchange experi-
ments) (Fig. S1). And second, the sequence-corrected
conformational shifts (28–30) (Δδ) of Hα protons in the
polypeptide patch Asp190-Arg192 were outside the commonly
accepted range for random-coil peptides (|Δδ| ≤ 0.1 ppm)
(Tables S1 and S3). The 13C chemical shifts of the Cα and Cβ of
the residues labeled (i.e., Arg186, Val188, Gly189, Arg192,
Lys193, Ile195, Ala197, Leu198, Gly200, Gly203, Arg204,
Lys205, Lys206, Lys207, and Phe208) were not very different
from those reported for random-coil polypeptide chains (30)
(Table S3).
We performed NMR experiments in the presence of 50%
TFE, when the titration of both peptides had reached a plateau
(Fig. 2B). Both the NOE pattern (presence of NN(i, i + 1),
NN(i, i + 2), NN(i, i + 3), αN(i, i + 3), αN(i, i + 4), αβ(i, i + 3)
contacts) (Fig. 3, C–D) and the conformational shifts of the Hα
protons (Tables S2 and S4) indicate the presence of helix-like
conformations between Trp191 and Gly200. This polypeptide
patch involves the same region acquiring an α-helix (α5 helix)
in the whole TnI-TnC-TnT2 complex (PDB accession number
1VDI) (31). It is important to note that the organic solvent
does not induce helical structure, but it only enhances the
population of this structure in those regions with an intrinsic
tendency to acquire such type of conformation.
To investigate whether different pH yielded a different NOE
pattern in NMR experiments for the helicities of the two
peptides, we also carried out experiments at pH 4.5
(Tables ST6 and ST7) for both peptides to test experimentally
the qualitative predictions of AGADIR (22–27), which sug-
gested a lower percentage of helical structure at this pH due to
global electrostatic effects in the peptides: 1.00% for the wild-
type peptide and 0.70% for the myopathic mutant. As seen atJ. Biol. Chem. (2021) 296 100228 3
Figure 2. CD spectra of HcTnI-C27 and HcTnI-C27-H peptides. A, far-UV
CD spectra at pH 7.2 and 5 C. B, the sigmoidal change in the [Θ] at 222 nm,
[Θ]222, as the TFE concentration was increased. The line is the fitting to a
two-state model (20, 21). C, AGADIR (22–27) helical percentages for both
peptides.
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4 J. Biol. Chem. (2021) 296 100228pH 7.0 described above, we observed that in HcTnI-C27 the
sequential amide–amide NOEs between Val188-Gly189,
Asp190-Trp191, Lys193-Asn194, Ile195-Asp196, Met201-
Glu202, and Gly203-Arg204 were detected. On the other
hand, for HcTnI-C27-H, only the amide–amide NOEs be-
tween Asn194-Ile195, Met201-Glu202, and Gly203-Arg204
were observed. Thus, the number of sequential NOEs, char-
acteristic of a nascent helix, in both peptides at pH 4.5 was
smaller than at physiological pH (Fig. 3).
To further confirm the propensity of the peptides to
populate helical conformations, we carried out MD simula-
tions for 50 ns in explicit solvent using the water model TIP3P
(32). The starting structures were built on the basis of the TnI-
TnC-TnT2 complex (31). Figure 4 shows that in the structure
of the wild-type peptide HcTnI-C27, the number of hydrogen
bonds forming α-helical structure decreased from the initial
number (about 13–15 hydrogen bonds), and after 25 ns
equilibrated to a final value of 5. In contrast, the HcTnI-C27-H
peptide was less stable and lost all its structure before the end
of the simulation. This finding is a direct indication of a
decreased helical propensity due to the Arg192His mutation
(in agreement with the far-UV CD results, the TFE titration,
the deconvolution of far-UV CD spectra, and the NMR re-
sults). Figure 5 reports in detail the type of secondary structure
of the wild-type peptide obtained at equilibrium as a function
of the residues. The results show that a residual α-helix was
present starting at the Trp residue and extended up to the
following four amino acid residues along the sequence.
The NMR and MD data conclude that, at residue level,
isolated HcTnI-C27 had native helix-like structure in aqueous
solution around Trp191 and a tendency to extend it into the
following few residues. On the other hand, HcTnI-C27-H had
a smaller population of helix-like structures and, thus, this
mutation disrupted (although not fully) the structure around
the aromatic moiety.
Binding of HcTnI-C27 and HcTnI-C27-H peptides to
tropomyosin
We further tested the binding of HcTnI-C27 and HcTnI-
C27-H peptides to Tm, a potential target of TnI’s inhibitory
regulation of the activation and deactivation of myofilaments
(11, 12). First, we monitored the binding by using far-UV CD
measurements for the formation of complex of equimolar
amounts of the corresponding peptide and protomer of
tropomyosin. HcTnI-C27 showed small changes in the addi-
tion spectrum (obtained by the sum of the spectra of isolated
αTm and HcTnI-C27) and that of the complex (Fig. 6A). On
the other hand, HcTnI-C27-H showed changes similar to
those of the wild-type peptide (Fig. 6B), but the variations were
in the opposite direction. We explored the binding between
αTm and the peptides in thermal-denaturation experiments
followed by CD. If such binding occurs for both peptides, the
thermal denaturation midpoint of the potential complexes
should increase when compared with that of αTm alone.
Figure 6C shows that is indeed the case. In the presence of
Figure 3. NMR structure of HcTnI-C27 and HcTnI-C27-H peptides. Summary of NMR data for the peptides under different conditions is shown. NOEs are
classified into strong, medium, or weak according to the height of the bar underneath the sequence. The contacts were measured in the ROESY experiment.
The dotted lines indicate NOE contacts, which could not be unambiguously assigned due to signal overlapping. The residue numbering corresponds to that
of the whole sequence of human cardiac TnI. The symbols αN, βN, γN, and NN represent the sequential contacts between the corresponding protons of
adjacent residues.
Structure and function of C-terminal peptide of troponin Ipeptides, the midpoint of the thermal denaturation of αTm
increased from 43.1 C ± 0.3 deg. C (316.25 ± 0.3 K) to
46.7 C ± 0.2 deg. C (319.85 ± 0.2 K) for HcTnI-C27 and
47.7 C ± 0.4 deg. C (320.25 ± 0.4 K) for HcTnI-C27-H.
Therefore, the results show unambiguously that both peptides
bound αTm and that upon binding there were changes in the
structure of the peptides and/or tropomyosin.
Although peptide binding affinity and protein structural
stabilization are intimately related, there is no direct correla-
tion (that is, peptides exhibiting the same affinity do not
necessarily induce the same stabilization effect). Therefore,
protein stability increments are not useful to rank peptide
binding affinities, and the increased stability observed upon
thermal-denaturation may be the result of unspecific in-
teractions between the peptides and Tm. To quantitatively
measure the binding between both peptides and tropomyosin,
we carried out titration fluorescence measurements and ITCexperiments. The fluorescence results yielded a Kd of 8 ± 4 μM
and 15 ± 5 μM for HcTnI-C27 and HcTnI-C27-H mutant
peptides, respectively (Fig. 7A). On the other hand, the ITC
results (Fig. 7B) showed that the binding of wild-type peptide
to αTm was characterized by a very small enthalpy change
(0.35 ± 0.02 kcal/mol), which precluded the determination of
the dissociation constant with high precision (raw data of the
ITC for the wild-type peptide are shown in Fig. S2). Never-
theless, the estimated Kd value obtained from ITC for the wild-
type peptide (11 ± 4 μM) is in line with the ones obtained from
fluorescence. Accordingly, the binding of HcTnI-C27 to αTm
is entropically driven, suggesting that the release of water
molecules upon binding and structure gain (see below) may
play a key role in the energetics of the molecular recognition
process. We could not measure the affinity of HcTnI-C27-H
by ITC because the curves were noisy and they did not yield
any reliable Kd. From the fluorescence data, we can alsoJ. Biol. Chem. (2021) 296 100228 5
Figure 4. Simulated secondary structure of HcTnI-C27 and HcTnI-C27-H
peptides. Number of hydrogen bonds forming α-helical structure obtained
in MD study is plotted as a function of time for HcTnI-C27 (black) and HcTnI-
C27-H (red). For clarity, data are averaged over a 100-point time window.
Structure and function of C-terminal peptide of troponin Iconclude that the affinity of the myopathic mutant peptide for
αTm was lower than that of the wild-type peptide. It is
important to note that the differences in the values of the
dissociation constants obtained by fluorescence were small.
However, it is evident that (i) the ITC only yielded a reliable
value for the wild-type peptide; and (ii) this value was similar
to that measured by fluorescence analysis, supporting that
there were small, but distinct differences in the binding of the
two peptides to αTm. On the other hand, the fact the HcTnI-
C27-H induced a larger variation in the thermal denaturation
midpoint, Tm, of the thermal denaturation of the complex
compared with that of isolated αTm could imply a higher af-
finity. The change in Tm induced by a ligand (peptide) on a
protein depends on: (i) the affinity of the interaction; (ii) ligand
and protein concentration; (iii) the enthalpy of the binding
reaction; and (iv) the heat capacity of such reaction. The last
two thermodynamic parameters are important because they
govern how the affinity of the complex changes with the
temperature (the van’t Hoff equation) and our thermalFigure 5. Residues with secondary structure in HcTnI-C27 peptide.
Details of the secondary structure obtained in simulation in the time win-
dow of 25 to 50 ns are shown as that when the number of hydrogen bonds
involved in α-helical structures has reached a plateau (see Fig. 4). A
persistent presence of α-helix is visible starting from residue Trp191.
6 J. Biol. Chem. (2021) 296 100228denaturation study is probing the thermal unfolding of the
corresponding complex. If a ligand has an endothermic
enthalpy in a binding reaction, when the temperature in-
creases, the affinity of the complex rises until the enthalpy
(positive because it is endothermic) gets null, and then
(assuming the heat capacity of the binding reaction is negative)
from that temperature on, the affinity decreases because the
enthalpy is becoming negative (exothermic). On the other
hand, if the ligand has an exothermic enthalpy, when we in-
crease the temperature, the affinity decreases upon raising the
temperature. The different value of the enthalpy and the
different heat capacity for the wild-type and the myopathic
peptide result in a value of the Tm larger for the complex of the
latter.
We then addressed the question whether the structure ac-
quired by HcTnI-C27 in the presence of αTm was the same as
that acquired by the mobile C-terminal domain of TnI in the
TnI-TnC-TnT complex (31) by using transferred NOESY (tr-
NOESY) (Fig. 3E) in the presence of submicromolar concen-
trations of αTm (Table S5 and Fig. S3). The presence of NN(i,
i + 1), NN(i, i + 2), αN(i, i + 2), βN(i, i + 2), βN (i, i + 3)
contacts indicates that HcTnI-C27 was adopting a helix-like
structure around Trp192, encompassing similar residues as
in the α5 helix of the mobile domain of the TnI-TnC-TnT2
(31); the number of NN(i, i + 1) contacts was very similar to
those measured in isolated peptide in aqueous solution, but
their intensity was higher (Fig. S3); furthermore, the stability of
the helix was not very high, as there were no protected amide
protons in D2O for the peptides (Fig. S1). We tried to obtain a
structure, by using CYANA software (33), with the 79 NOEs
measured in tr-NOESY for the wild-type peptide, and none of
them involving residues more than five amino acids apart.
Such amount of NOEs for a peptide of this length is very small,
and it probably yields a structure that is not reliable. In fact,
the 20 obtained structures by CYANA had a very low target
function (mean of 0.23), but they showed a high root mean
square deviation (RMSD) of 4.12 ± 0.76 (for all backbone
atoms from Arg186 to Lys207), and the percentage of residues
in the most favored regions of the Ramachandran plot was very
low (16.7%), although there were no residues in the disallowed
regions.
The binding was mapped by using relaxation measurements
in the absence or presence of αTm at a protomer concentra-
tion five times of that of the peptide. It is important to indicate
that upon addition of such amount of αTm, we did not observe
any large variation in proton chemical shifts of the cross-peaks
for most of the labeled residues (i.e., Arg186, Val188, Gly189,
Arg192, Lys193, Ile195, Ala197, Leu198, Gly200, Gly203,
Lys205, Lys206, and Phe208), but we only noticed changes in
chemical shifts for Arg204 and Lys207 near the C terminus of
the peptide (as shown by the chemical shift perturbation
(CSP), Fig. S5). However, we did observe a broadening of all
cross-peaks in the presence of αTm (Fig. S4). This broadening
resulted in a quantitatively measured increase of the R2 rates
(see below) and it indicates that the dynamics of the peptide
(in the nanosecond-to-millisecond time regime) is modified by
the presence of αTm. In the absence of tropomyosin, the
Figure 6. Binding of HcTnI-C27 and HcTnI-C27-H peptides to αTm shown in far-UV CD spectra. A, far-UV CD spectra of the equimolar complex formed
by HcTnI-C27 and αTm and that obtained by the addition of the spectra of both isolated molecules. B, far-UV CD spectra of the equimolar complex formed
by HcTnI-C27-H and αTm and that obtained by the addition of the spectra of both isolated molecules. C, thermal denaturation monitored by ellipticity
changes at 222 nm for isolated αTm, and its complexes with HcTnI-C27 and HcTnI-C27-H peptides.
Structure and function of C-terminal peptide of troponin Ipeptides move faster showing smaller R2 values, indicating
interactions between the peptide and αTm in solution and
different conformational exchanges. It is important to note at
this stage that we were not able to measure properly theFigure 7. Binding of HcTnI-C27 and HcTnI-C27-H peptides to αTm shown in
obtained by excitation at 280 nm after subtraction of the intensity of the spe
through the experimental points is the fitting to Equation 1. B, the isotherm fro
25 C shows the enthalpy change upon binding as a function of the peptide to
data are provided in Supplementary Materials.intensity of Arg204 in the 1H-15N {NOE} spectrum of the
bound peptide although we were able to measure its R1 and R2
rates, which were 2.3 ± 0.3 s−1 and 5.1 ± 0.7 s−1, respectively.
The values of the R1 rates for all residues were not significantlyfluorescence and ITC assays. A, titration fluorescence intensities at 350 nm
ctrum of the isolated peptide at the corresponding concentration. The line
m calorimetric titrations of αTm with HcTnI-C27 in phosphate buffer, pH 7.0,
protein molar ratio. The line is the fitting to a 1:1 binding equation. The raw
J. Biol. Chem. (2021) 296 100228 7
Figure 8. Docking of HcTnI-C27 peptide on tropomyosin. Representative
conformations of the wild-type peptide in the two predicted binding lo-
cations of tropomyosin are shown with protein residues explicitly labeled.
For clarity, the peptide main chain (cyan) is represented omitting the O and
H atoms, whereas the side chains have atoms in standard colors.
Structure and function of C-terminal peptide of troponin Imodified in the presence of αTm (Fig. S6A) and remained
similar (a mean of 2.32 ± 0.22 s−1 for the bound peptide; and a
mean of 2.17 ± 0.14 s−1 for the isolated peptide). On the other
hand, the R2 rates of all residues increased in the presence of8 J. Biol. Chem. (2021) 296 100228αTm, indicating binding between the two molecules. Although
the resonances of Arg192 and Lys193 did not show any change
in chemical shifts, they showed large variations in the R2 rates
(Fig. S6B). In addition, the NOE values also showed the largest
variations for Arg192, Lys193, Ile195, and Ala197, presenting
values larger in the free peptide than in the αTm-bound form
(Fig. S6C).
Molecular docking was performed to predict the most
favorable binding location of HcTnI-C27 peptide on the surface
of Tm dimer. Due to the exceedingly large number of degrees of
freedom in the peptide structure, a crude approximation was
used that consisted of allowing rotations only around its main
chain u and ψ dihedral angles and with the exclusion of those
with secondary structure maintained in theMD simulations (i.e.,
around Trp191). The results indicated that the most favorable
docking poses (with predicted binding energy of about −6.5 kcal/
mol) clustered around two distinct locations (Fig. 8). One was in
correspondence of residue Cys190 of tropomyosin, which is a
site that has been documented for physiological importance,
whereas the other was in between the two consecutive acidic
residues Glu163 and Glu164. In both cases, Trp191 of HcTnI-
C27 appeared to be a key residue in the binding due to its abil-
ity to form hydrophobic interactions with Tmwith an additional
effect on the side chain of Ile195 in the subsequent turn of the α-
helix. This modeling result supports the findings of fluorescence
analysis, where we followed the changes in tryptophan fluores-
cence to map the binding to Tm (Fig. 7A). The modeling study
suggests a possible rationale for the stabilization of the helical
structure in the binding site, which would explain the further
extension of the helical conformation up to residue Leu198, as
indicated by the tr-NOESY results (Fig. 3E). Electrostatic in-
teractions also played a role in the binding of HcTnI-C27 and
Tm, especially in the second location identified, due to the
charge–charge attraction with the small acidic patch present on
the protein surface. Such interactions would be partially dis-
rupted by the Arg192Hismutation in theHcTnI-C27-H peptide.
These long-range electrostatic interactions could explain the
change in the chemical shifts of the cross-peaks of positively
charged Arg204 and Lys207 (see above) (Fig. S4) in the presence
of a fivefold (protomer) amount of αTm, although they are
located far away from Trp191.
Impaired effect of the myopathic mutant peptide HcTnI-C27-H
on myofibril contractility
To establish the functional significance of the structural
data, contractility studies showed that the addition of HcTnI-
C27 peptide reproduced the Ca2+-desensitization effect with a
right shift of the force-pCa curve in skinned mouse cardiac
muscle strips (Fig. 9A) as reported previously (12). The effect
was greater at longer sarcomere length of 2.3 μm than that at
sarcomere length of 2.0 μm (Fig. 9A). In comparison, the
HcTnI-C27-H mutant peptide had no Ca2+-desensitization
effect at sarcomere length of 2.0 μm and less effect at sarco-
mere length of 2.3 μm (Fig. 9B). Whereas HcTnI-C27 peptide
plausibly does not affect maximum force (Fig. 9A), HcTnI-27-
H significantly decreased maximum force production,
Figure 9. HcTnI-C27 reduces Ca2+ sensitivity of skinned mouse cardiac muscle, whereas HcTnI-C27 has a weaker effect. A, force–pCa curves show
that the treatment with HcTnI-C27 decreased Ca2+ sensitivity of skinned mouse ventricular papillary muscle with larger effect at sarcomere lengths (SL) of
2.3 μm than that at SL 2.0 μm. The maximum force production was not affected (the inset bar graph). B, HcTnI-C27-H mutant peptide had less effect at SL of
2.3 μm and no effect at SL of 2.0 μm. The maximum force production was not affected at SL 2.0 μm but significantly decreased by the adding of HcTnI-C27-
H mutant peptide at SL of 2.3 μm (the inset bar graph). Ca50, Ca2+ concentration for 50% maximum force. Values are presented as mean ± SE. N = 5 in
HcTnI-C27 studies and N = 6 in HcTnI-C27-H studies. Statistical analysis was done using one-way repeated measures ANOVA following with pairwise
comparison. *p < 0.05 and **p < 0.01 HcTnI-C27 peptide treatment versus control; #p < 0.05 and ##p < 0.01 SL 2.3 μm versus SL 2.0 μm.
Structure and function of C-terminal peptide of troponin Iindicating an impaired function possibly underlying the car-
diomyopathic phenotype of the Arg192His mutation in cardiac
TnI (13).
HcTnI-C27 has potent Ca2+-desensitization effect on skinned
cardiac muscle of transgenic mouse containing a hypertrophic
cardiomyopathy mutation in cardiac αTm
Force-pCa studies showed that skinned sections from
transgenic mouse left ventricular papillary muscle expressing a
hypertrophic cardiomyopathy mutation E180G in cardiac αTm
(Tm180G) (34) had the anticipated higher Ca2+ sensitivity than
that of wild-type cardiac muscle (Fig. 10). At sarcomere length
2.0 μm, the treatment of 20 μM HcTnI-C27 had a notably
larger Ca2+-desensitization effect on Tm180G cardiac musclethan that on wild-type muscle (Fig. 10A). At sarcomere length
2.3 μm, HcTnI-C27 had much higher Ca2+-desensitization
effects on Tm180G cardiac muscle (Fig. 10B). With the sig-
nificant myofilament Ca2+-desensitization effect especially at
higher [Ca2+] corresponding to activated state, HcTnI-C27 did
not decrease maximum force development of the failing
Tm180G cardiac muscle. The results demonstrate an
appealing therapeutic function of HcTnI-C27 peptide for the
treatment of hypertrophic cardiomyopathies and heart failure
with diastolic dysfunction.
Discussion
TnI is the inhibitory subunit of troponin and plays a
critical role in regulating muscle contraction and relaxationJ. Biol. Chem. (2021) 296 100228 9
Figure 10. Therapeutic effect of HcTnI-C27 on alleviating the Ca2+ hypersensitivity of skinned papillary muscle strips of Tm180 G mice. Force–pCa
relationship was studied at sarcomere length (SL) of 2.0 μm (A) and 2.3 μm (B) for the effect of 20 μM HcTnI-C27. The maximal force development, pCa50
(the Ca2+ concentration at 50% of the maximum force at pCa 4.5), and Hill fitting of data normalized to maximum force for the cooperativity of Ca2+-
activation are shown in the inset tables. Tm180G hypertrophic failing cardiac muscle with higher Ca2+-sensitivity (higher pCa50) than wild-type (WT)
controls at SL of 2.0 μm and 2.3 μm. HcTnI-C27 treatment decreased Ca2+-sensitivity of Tm180G cardiac muscle significantly more than that of WT control
especially at SL of 2.3 μm. The Ca2+-desensitization effect of HcTnI-C27 peptide is more potent at higher [Ca2+] corresponding to the activated state and
does not decrease the maximal force development. Values are presented in Mean ± SE. N = 6 fibers in WT and n = 3 in Tm180G. *p < 0.05 versus WT in
unpaired Student’s t-test; #p < 0.05 versus control in paired Student’s t-test.
Structure and function of C-terminal peptide of troponin I(3, 35). We recently reported that free peptide of the highly
evolutionarily conserved C-terminal 27-residue-long end
segment of TnI (C27, Fig. 1A) retains a native epitopic
structure in solution and the endogenous binding affinity for
tropomyosin (12). Adding free HcTnI-C27 peptide to skin-
ned cardiac muscle strips produced an activated state-
specific Ca2+ desensitization effect, demonstrating a novel
mechanism to improve muscle relaxation (12). Cardiac
muscle dysfunction, especially diastolic dysfunction, and
heart failure are a worldwide medical challenge that lacks
effective treatment. Myocardial contractility is essential for
heart function and an ultimate target for the treatment of10 J. Biol. Chem. (2021) 296 100228heart failure. The diastolic function of cardiac muscle de-
termines the efficacy of ventricular filling and is critical to
cardiac pumping based on the Frank–Starling mechanism.
More that 50% of clinical heart failure cases are due to
diastolic dysfunction that currently has no specific treatment
(36). Derived from the inhibitory subunit of troponin, the
HcTnI-C27 peptide is a promising therapeutic reagent of
physiological function and safe endogenous origin. To
investigate the molecular basis of the effect of HcTnI-C27
peptide on myofilament function for the treatment of dia-
stolic heart failure, the results of our present study provide
the following mechanistic insights.
Structure and function of C-terminal peptide of troponin IFree C27 peptide populates a nascent helix in aqueous
solution
The first result of our far-UV CD and NMR studies is that
both HcTnI-C27 and HcTnI-C27-H peptides populated helical
structures around Trp191. This population was smaller in
HcTnI-C27-H containing the Arg192His mutation that causes
diastolic dysfunction of the heart (13). The simulation results
further suggest that the helical structure is labile, with disor-
dered states prone to form transient hydrogen bonds.
The helical population seemed to be triggered by the pres-
ence of Trp191, as larger number of sequential NN(i, i + 1)
NOEs were clustered around those residues (Fig. 3), consistent
with the observation that tryptophan residues are involved in
triggering helical structure or hydrophobic clusters in free
peptides (37–39). Our MD study also indicated that the helical
propensity of the Trp residue extends to the four downstream
amino acids along the sequence. It is worth noting that the
presence of an arginine immediately after the tryptophan in-
creases the population of the helical structure, as judged by the
differences observed in far-UV CD and NMR (Figs. 2 and 3).
The introduction of a bulky side chain close to the indole
moiety as that of the imidazole ring of the Arg192His mutation
in HcTnI-C27-H probably hampers backbone hydrogen-bond
formation and promotes helix disruption. However, we cannot
rule out the importance of electrostatic interactions in the
triggering of a helical fold in the isolated peptides among the
side chains of either His192 or Arg192 with those of Asp190 or
Asp196 (the closest residues) or other amino acids located
farther away; in fact, the NMR spectra of both peptides at pH
4.5 showed basically the same chemical shifts for most of the
protons, except for those belonging to Glu or Asp residues in
the polypeptide chain (Tables ST6 and ST7), which are
titrating in that pH interval. In addition, the presence of an
arginine close to the tryptophan could allow the formation of a
hydrogen bond between both side chains, as it has been
observed in X-ray crystallography structures of protein com-
plexes (40). The Arg192His mutation in cardiac TnI causes
severe diastolic functions of the heart (13), and the impaired
helical propensity of HcTnI-C27-H peptide suggests a likely
molecular mechanism underlying the pathogenesis.C27 peptide binds αTm with micromolar affinity
Our results show that HcTnI-C27 binds αTm with an af-
finity in the order of low micromolar (10 μM). This finding is
in agreement with the previous report that the HcTnI-C27
peptide is capable of competing at low micromolar concen-
tration with intact bovine cardiac TnI for binding to αTm,
whereas the HcTnI-C27-H mutant peptide showed a
decreased effect in the competitive binding assay (12). Sup-
porting this notion, our fluorescence measurements in the
present study show that the Tm-binding affinity of HcTnI-
C27-H was lower than that of the wild-type peptide (Fig. 7A),
and it did not result in a detectable amount of heat uptake
during ITC protein binding experiment. We suggest that the
decreased affinity of the mutant peptide was due to its smaller
population of helical structure, and then, the entropy variation,ΔS, occurring upon binding was much larger for HcTnI-C27-
H, decreasing the value of the ΔG. Therefore, a high popula-
tion of nascent helix is critical to attain binding of αTm at
physiological conditions. As a pathological consequence, the
reduced Tm-binding affinity of the Arg192His mutation may
impair the inhibitory function of TnI during the relaxation of
the cardiac muscle to cause diastolic dysfunction and severe
restrictive cardiomyopathy (13).
Upon binding to αTm, the structural dynamics of the
peptide was altered (Fig. S6) due to complex formation.
However, the conformation of the peptide was not altered in
the presence of αTm, as shown by the absence of changes in
chemical shifts in the HSQC spectra (Fig. S4). In addition, not
all residues showed the same variations in the R2 and NOE
values with the largest variations in chemical shifts located at
the C terminus (Fig. S6), and a larger number of sequential
NN(i, i + 1) NOEs located around Arg192 and Lys193 (Fig. 3).
These findings indicate that those residues were affected by
severe conformational exchange upon binding and were
probably among the first to bind αTm in the encounter
complex. Interestingly, the NOE values were higher in the
isolated peptide than in the bound species, indicating that
upon binding to Tm the peptide became more disordered in
the nanosecond-picosecond time regime. This behavior
(disorder upon binding), also known as cryptic disorder, has
been described in proteins involved in signaling pathways
(41–44), where a particular region of the polypeptide chain
changes its structure. To the best of our knowledge, our data
report for the first time the cryptic disorder in an isolated
peptide where the binding with a physiological partner pro-
tein induced substantial change in dynamics. This property
suggests a conformational selection mechanism upon binding
to αTm, favoring a specific conformation within the ensemble
explored by the peptide with a higher flexibility at particular
residues (Arg192, Lys193, Ile195, and Ala197) in the time-
scale of nanoseconds to picoseconds, whereas the dynamics
of the rest of the residues was unchanged. Therefore, the
HcTnI-C27 mutant is capable of tuning and modulating its
sustained binding to αTm and function, by modifying the
dynamics of particular residues involved in the nascent-
helical structure.
While NMR spectra could not provide any indication of the
anchoring region of HcTnI-C27 on Tm, the docking study
indicated two potential sites with favorable binding affinity, in
correspondence of residues Cys190 and of the small acidic
patch Glu163-Glu164 in αTm. The docking technique was not
capable of supplying direct information on the dynamics of the
peptide, but it suggested a molecular conformation that favors
the stabilization of a helix-like conformation based on the
possibility of forming hydrophobic interactions driven by
residues Trp191, Ile195, and Leu198 in HcTnI-C27. Hydro-
phobic surfaces are important in forming encounter com-
plexes (45), or recently for the complex between a protein and
a peptide (46). Accordingly, our docking findings suggest that
the Arg192His mutation in HcTnI-C27-H peptide would
disrupt the key binding region on the peptide surface, dis-
favoring the association with tropomyosin.J. Biol. Chem. (2021) 296 100228 11
Structure and function of C-terminal peptide of troponin IThe myopathic mutant peptide HcTnI-C27-H has decreased
Ca2+ desensitization effect
The primary function TnI is the inhibitory regulation of
muscle contraction, which is critical to muscle relaxation and
diastolic function of the heart (3, 35). Heart failure with pre-
served ejection fraction (HFpEF) is a common clinical condi-
tion that has no specific treatment for (47). The myofilament
Ca2+-desensitizing effect of HcTnI-C27 peptide is derived
from the endogenous function of TnI and demonstrates an
approach to selectively modulate contractile kinetics down-
stream of Ca2+ activation without reducing maximum force
production (Fig. 9A). Supporting the plausible effect of HcTnI-
C27 peptide on increasing diastolic function of cardiac muscle
as a potential treatment of HFpEF, HcTnI-C27-H peptide
containing the restrictive cardiomyopathy mutation
Arg192His (10) shows a detectable decrease in the Ca2+-
desensitizing effect but a significantly decreased maximum
force production (Fig. 9B), indicating the decreased population
of helical structure and absence of a folded conformation may
underlay the cardiomyopathy phenotype.
HcTnI-C27 peptide as a potent Ca2+-desensitizer for the
treatment of diastolic dysfunction of cardiac muscle
The results that HcTnI-C27 peptide has much larger Ca2+-
desensitization effect on Tm180 G mutant cardiac muscle than
that on WT muscle especially at longer sarcomeres (Fig. 10)
demonstrate a potent therapeutic function. E180 G mutation
in cardiac αTm causes severe hypertrophic cardiomyopathy
and heart failure with a feature of increased myofilament Ca2+
sensitivity (34). Similar to the effects on WT cardiac muscle
(12), the Ca2+-desensitization effect of HcTnI-C27 is signifi-
cantly higher at higher [Ca2+] corresponding to the activated
state (Fig. 10B). This feature is plausible to facilitate myocar-
dial relaxation without decreasing the maximum force devel-
opment (Fig. 10). Therefore, HcTnI-C27 peptide provides a
promising therapeutic reagent with high correcting effect on
diseased myofilaments for the treatment of hypertrophic car-
diomyopathies and diastolic heart failures.
Our comprehensive biophysical characterization of the C-
terminal end peptide of TnI demonstrated that the C-terminal
end domain of TnI can function as an isolated peptide that
preserves the intrinsic capacity of binding Tm in myofila-
ments, with physiological effect on tuning muscle contractility
and selectively improving diastolic function for use as a ther-
apeutic reagent for the treatment of heart failure. The much
less effect of HcTnI-C27 on WT (Fig. 9) than that on Tm180G
cardiac muscle strips (Fig. 10) demonstrates a correcting effect
that is safely restricted within physiological range. The data
describe a structure and mechanistic foundation for the
development of a new myofilament Ca2+ desensitizer to treat
diastolic heart failures while minimizing side effects.
Experimental procedures
Animals
All animal procedures were carried out using protocols
approved by the Institutional Animal Care and Use Committee12 J. Biol. Chem. (2021) 296 100228of Wayne State University and were conducted in accordance
with the Guiding Principles in the Care and Use of Animals, as
approved by the Council of the American Physiological
Society.
Materials
Wild-type, HcTnI-C27, and Arg192His mutant, HcTnI-
C27-H, peptides, comprising residues from Glu184 to Ser210
of human cardiac TnI (Fig. 1A), were synthesized using a
commercial service as described (12) with a nominal purity of
98%, which was confirmed by mass spectrometry to be larger
than 95%. Peptide concentrations were determined from UV
absorbance at 280 nm (48) of the sole Trp191 present in both
peptides.
15N,13C-labeled wild-type HcTnI-C27 peptide was produced
with labeled residues at: Arg186, Val188, Gly189, Arg192,
Lys193, Ile195, Ala197, Leu198, Gly200, Gly203, Arg204,
Lys205, Lys206, Lys207, and Phe208 (Fig. 1B) by chemical
synthesis at GenScript Biotech (New Jersey, USA) at a nominal
purity of 98%, which was confirmed by mass spectrometry to
be larger than 95%.
Rabbit cardiac α-tropomyosin (αTm) was purified from
frozen hearts using conventional biochemical methods as
described (12). The concentration of stock used in the present
study was estimated by UV absorbance at 278 nm from the six
Tyr residues in the sequence of the protomeric unit (48).
Deuterium oxide and 2,2,2-d3 trifluoroethanol (TFE) (96.5%
purity) were obtained from Apollo Scientific (Stockport, UK).
Sodium trimethylsilyl [2,2,3,3-2H4] propionate (TSP), deuter-
ated acetic and acetate sodium salt, and 2,2,2- trifluoroethanol
were from Sigma (St Louis, MO). All other chemicals used in
the study were analytical grade. Deionized water was purified
using a Millipore system.
Circular dichroism (CD)
Far-UV CD spectra were collected on a Jasco J810 (Tokyo,
Japan) spectropolarimeter interfaced with a Peltier unit.
Far-UV measurements were performed with 20 μM of each
peptide in 50 mM sodium phosphate buffer (pH 7.2) in 0.1 cm-
pathlength quartz cells (Hellma, Belgium) at 5 C. Experiments
in CD and NMR (see below) were carried out at low
temperature to increase the population of a possible folded
structure in the peptides (according to Boltzmann distribu-
tion). The band width was 1 nm, the response time was 2 s,
and the scan speed was 50 nm/min. Raw ellipticity was con-
verted to molar ellipticity, [Θ], and the amount of helical
populations was determined as described (49).
For experiments in the presence of TFE, the same set of
parameters as in aqueous solution experiments was used.
Cosolvent concentrations were indicated in v/v (%). The he-
lical populations for each peptide in the absence of cosolvent
were determined by assuming a two-state equilibrium: disor-
dered ↔ helical (as suggested by the presence of isodichroic
wavelengths during the titrations of both peptides) (20, 21).
For detecting peptide–protein binding using far-UV CD, we
prepared samples of HcTnI-C27 or HcTnI-C27-H with αTm
Structure and function of C-terminal peptide of troponin Iat an equimolar concentration (10 μM, in protomer units for
αTm). The rest of the experimental setup was the same as
described above.
Thermal-denaturation experiments for the αTm/peptide
complexes or αTm control were performed at constant heating
rates of 60 C/h and measured at a band width of 1 nm and
response time of 8 s. Thermal scans were collected by
following the changes in ellipticity at 222 nm from 20 to 90 C.
The apparent thermal-denaturation midpoint was estimated
from a two-state equilibrium equation as described (49).
Fluorescence spectroscopy
Fluorescence spectra were collected on a Cary Varian
spectrofluorimeter (Agilent, USA), interfaced with a Peltier
unit. Experiments were carried out in a physiological protein
binding buffer containing 100 mM KCl, 3 mM MgCl2, 10 mM
sodium phosphate, pH 7.0. The samples were prepared the day
before and stored overnight at 5 C and equilibrated at 25 C
for 1 h before the experiments. A 1 cm-pathlength quartz cell
(Hellma) was used.
Titrations of the binding between HcTnI-C27 or HcTnI-
C27-H peptide and αTm were performed with increasing
concentration of the peptides (0–15 μM) and a fixed con-
centration of αTm (10 μM protomer). Using excitation at 280
or 295 nm with excitation and emission slits of 5 nm, the
experiments were carried out at 25 C. The dissociation con-
stant of αTm/HcTnI-C27 or αTm/HcTnI-C27-H complexes,
Kd, was calculated by fitting the changes observed to the
following equation (50, 51):








where F is the measured fluorescence at any particular con-
centration of the peptides after subtraction of the blank signal;
ΔFmax is the maximal change in the fluorescence of the pep-
tides when the whole amount of αTm is forming the complex;
F0 is the fluorescence intensity when no peptide was added;
[αTm]T is the constant total concentration of αTm (10 μM);
and [HcTnI-C27i]T is that of the corresponding peptides,
which is varied during the titration. The titration was repeated
twice for each peptide. The absorbance of the corresponding
peptide was kept lower than 0.1 units (at 280 nm) to avoid
inner-filter effect during fluorescence excitation (52). Fitting
Equation 1 to the data was carried out using KaleidaGraph
(Synergy software, Reading, PA, USA).
NMR
NMR experiments for the assignment (at two pH values and
under different solvent conditions) and translational diffusion
measurements of the peptides were performed at 10 C on a
Bruker Avance DRX-500 (11.7 T) spectrometer (Karlsruhe,
Germany), equipped with a triple resonance probe and z-pulse
field gradients. The transferred NOESY (with a mixing time of300 ms) and the relaxation measurements were acquired in an
Avance-II 600 MHz spectrometer (14.1 T) equipped with a
triple resonance cryo-probe and z-pulse field gradients at
10 C. Temperature of both probes was calibrated with
methanol (53). All experiments with the peptides in aqueous
solution or in the presence of 50% TFE were carried out at pH
7.2 in 50 mM sodium phosphate buffer, except those acquired
at pH 4.5 to test for electrostatic effects in the isolated pep-
tides, which were acquired in 50 mM deuterated acetate buffer.
All spectra were referenced to external trimethylsilylpropanoic
acid (TSP), by taking into account the pH-dependence of its
signals (53). All samples, either in aqueous or TFE solutions,
contained 10% D2O to lock the sample.
Translational diffusion NMR experiments (DOSY)
The working concentrations for both HcTnI-C27 and
HcTnI-C27-H peptides were 100 μM. In each experiment, 64
scans were acquired. Translational self-diffusion measure-
ments were performed with the pulsed-gradient spin-echo
sequence in 100% D2O. The following relationship exists be-
tween the translational diffusion coefficient, D, and the delays
















where I is the measured peak intensity of the methyl reso-
nances at a gradient strength; I0 is the maximum peak intensity
of the methyl groups at the smallest gradient strength; D is the
translational self-diffusion constant; δ is the duration of the
gradient (2.25 ms); G is the gradient strength; Δ is the time
(200 ms) between the gradients; γH is the gyromagnetic con-
stant of the proton; and τ is the recovery delay between the
bipolar gradients (100 μs). The gradient strength was varied in
16 lineal steps between 2% and 95% of the total power of the
gradient coil of the probe. Data were plotted as I/I0 versus G
2,









, from where D can be obtained. The gradient strength
was calibrated by using the value of D for the residual proton
water line in a sample containing 100% D2O in a 5-mm tube
(49). In the samples containing both peptides, 1% of a final
concentration of dioxane was added as an internal size marker;
the hydrodynamic radius, Rh, of each peptide was obtained by
assuming that the R of dioxane is 2.12 Å (54). The DOSY
experiment was repeated twice for each peptide. Data were
fitted to Equation 2 by using KaleidaGraph.
2D-1H-NMR homonuclear spectroscopy
Two-dimensional spectra with a spectral width of 6000 Hz in
both dimensions were acquired in the phase-sensitive mode by
using the time-proportional phase incrementation technique
(TPPI) (55) for both peptides. Peptide concentrations were in the
range 1.0 to 1.3 mM. At pH 7.2, standard DQF-COSY, TOCSY
(80 ms), ROESY (250 and 300 ms), and NOESY (300 ms) exper-
imentswere performed; at pH4.5, onlyNOESYandTOCSY (with
the same mixing times as at pH 7.2) were acquired. StandardJ. Biol. Chem. (2021) 296 100228 13
Structure and function of C-terminal peptide of troponin Iphase-cycling sequences were used to acquire the complete set of
experiments to achieve assignments. The DQF-COSY experi-
ment (56) was acquired with a data matrix size of 4096 × 512 (t2
and t1, respectively) and 1 s of recycle delay, 128 scans per t1
increment, and with the residual water signal attenuated by pre-
saturation during the relaxation delay. TOCSY, ROESY, and
NOESY experiments were acquired with a data matrix size of
4096 × 512 (t2 and t1, respectively); for the TOCSY, we used the
MLEV17 spin-lock sequence (57), with a mixing time of 80 ms.
Eighty scans were acquired per t1 increment, the residual water
signal was removed by using the WATERGATE sequence (58).
NOESY and ROESY spectra (59, 60) were collected with 128
scans per t1 increment in both types of experiments, with the
residual water signal removed in both experiments by the
WATERGATE sequence. Mixing times were 300 ms. Data were
zero-filled, resolution-enhanced, baseline-corrected with phase-
shifted sine bell (for DQF-COSY) or square sine-bell window
functions (for TOCSY, NOESY and ROESY), optimized in each
spectrum, and processed with the Bruker TopSpin 2.1 software.
1H NMR resonances were assigned by standard sequential
assignment processes (28). The random-coil chemical shift values
of Hα protons were obtained from tabulated data in model pep-
tides, corrected by neighboring residue effects (29, 30).
We also acquired tr-NOESY with unlabeled HcTnI-C27 at
600 MHz, with the same experimental setup described above,
but a spectral width of 7200 Hz, and in the presence of the
binding buffer (100 mM KCl, 3 mM MgCl2, 10 mM sodium
phosphate, pH 7.0). Peptide concentration was 1.1 mM and
that of αTm was 45.7 μM (protomer).
1H, 15N-HSQC spectra and triple resonance experiments
The HSQC spectra of double-labeled HcTnI-C27 were ac-
quired as described (61) at 14.1 T with 40 μM free peptide or
20 μM of double-labeled peptide and 104 μM (protomer) of
αTm in the binding buffer. Other experimental details are as
described previously (61). The 1H carrier was at the water
frequency, which was removed by using the WATERGATE
sequence (58); the spectral width in this dimension was 9 ppm.
The 15N carrier was set at 120 ppm, and the spectral width in
this dimension was 30 ppm.
We define the chemical shift perturbation (CSP) of the





where ΔδH is the variation in
the chemical shifts of the amide proton between the values in
the HSQC spectra of wild-type peptide in the presence and in
the absence of αTm, and the ΔδN is the corresponding dif-
ference for the 15N nucleus.
Standard triple resonance experiments (53) were acquired in
a Bruker 500 MHz magnet, with a concentration of 1.1 mM, to
allow determination of the 15N and 13C frequencies for the
labeled residues.
Relaxation measurements
NMR relaxation data included the acquisition of 15N-R1,
15N-R2 and
1H-15N {NOE} experiments with the double-
labeled HcTnI-C27. Two samples were prepared, one with a14 J. Biol. Chem. (2021) 296 100228concentration of 40 μM of double-labeled HcTnI-C27 in
binding buffer; and the second containing 20 μM of double-
labeled peptide and 104 μM (protomer) of αTm in the same
buffer. All the relaxation measurements were determined in an
interleaved manner to ensure that the experimental conditions
were the same for the different relaxation delays. The 15N-R1,
15N-R2, and
1H-15N {NOE} experiments were acquired for
both samples by using enhanced sensitivity, gradient pulse
sequences (63). The T1 (=1/R1) was measured in an interleaved
way with typically 7 inversion-recovery delays, varying from 10
to 550 ms; T2 (=1/R2) was determined by collecting seven time
points ranging from 10 to 400 ms. For the T1 and T2 pulse
sequences, the delay between scans was 1.5 s. The 1H-15N
{NOE} was measured by recording interleaved spectra in the
absence or presence of proton saturation. The 1H-15N {NOE}
spectrum recorded in the presence of proton saturation was
acquired with a saturation time of 10 s. The 1H-15N {NOE}
spectrum recorded without proton saturation incorporated a
relaxation delay of 10 s. The 1H-15N {NOE} experiment (with
and without saturation) was repeated twice for each sample.
Spectra were recorded with 2048 × 180 complex matrices in
the F2 and F1 dimensions, respectively, with typically 160 scans
(NOE experiment) and 128 scans (R1 and R2 experiments) per
F1 experiment. Spectral widths of 9 and 30 ppm were used for
F1 and F2, respectively; the
15N carrier was set at 120 ppm and
that of 1H was set on the water signal in all the experiments.
All the spectra were zero-filled in the F1 dimension (two to
four times) and processed by using a shifted sine square window
function in Topspin 2.1 software package (Bruker). The same
window function was used throughout all the T1 and T2 exper-
iments. Intensities of the cross-peaks were measured with
Topspin 2.1. The R1 and R2 values were determined by fitting the
measured peak-intensities to a two-parameter function: I(t) =
I0exp (−tR1,2), where I(t) is the peak intensity after a relaxation
delay t, and I0 is the intensity at time zero; uncertainties in the
relaxation rates were error fittings from the above equation. The
experimental data were fitted to such equation by using Kalei-
dagraph. The steady-state 1H-15N {NOE} values were deter-
mined from the ratios of the peak intensities with and without
proton saturation (i.e., NOE = Isat/Inonsat). The uncertainties of
the NOE values were determined from the measured back-
ground noise levels during repeated experiments.1D 1H-NMR spectra in D2O
1D spectra were acquired in D2O with peptide concentra-
tions in the range 30 to 50 μM in isolation or in the presence of
submicromolar amounts of αTm (the buffers were those
described above for the acquisition of HSQC spectra). The
isolated peptides (or in the presence of the protein) were
dissolved in D2O and kept on ice, while the magnet was
shimmed with a dummy sample. Experiments were acquired
with the WATERGATE sequence at 10 C in the Avance
DRX-500 (11.7 T) spectrometer. A number of 512 scans was
acquired with a total matrix size of 32 K. The spectra were
processed with Bruker TopSpin 2.1 software by using an
exponential window function and apodized until 64 K.
Structure and function of C-terminal peptide of troponin IIsothermal titration calorimetry (ITC)
ITC experiments were carried out at 25 C using a VP-ITC
instrument from Microcal (Northampton, USA). αTm solution
was dialyzed at 4 C for 24 h against three changes of 2 l of
10 mM sodium phosphate, pH 7.0, containing 100 mM KCl
and 3 mM MgCl2. The ligands (HcTnI-C27 and HcTnI-C27-H
peptides) were dissolved in the same buffer recovered from the
last dialysis of αTm. The ITC experiments involved sequential
injections of 10 μl of stock solutions of concentrated ligand
(609 μM for HcTnI-C27, and 723 μM for HcTnI-C27-H)
loaded in a syringe connected to the calorimetric cell (1.4 ml)
that contained αTm at a concentration of 30 μM (protomer).
To correct for the heat evolved due to the dilution effect of
adding the ligand solution to the calorimetric cell, an inde-
pendent experiment was performed in which the same ligand
solution was injected into the calorimetric cell loaded with
buffer. After correction for the heat of dilution, the isotherm
was fitted to the binding model assuming the existence of a
single set of binding sites, by using the software provided by the
manufacturer.
Bioinformatic calculations
AGADIR (www.crg.es) (22, 23) website was used to predict
the helical percentage of both peptides. DICHROWEB website
(www.dichroweb.cryst.bbk.ac.uk) (18, 19) was used to predict
the percentage of helical structure in both peptides from their
far-UV CD spectra in aqueous solution.
Molecular simulations
All-atom MD simulations were performed using the GRO-
MOS simulation suite (64) with the force field Amber ff99SB-
ILDN (65). The structure of the two peptides was built using
the software Visual Molecular Dynamics (66), starting from the
solution structure of the potential actin-binding domain of TnI
reported in the entry 1VDI (31) in the Protein Data Bank. The
peptides were solvated using the water model TIP3P (32). A
simulation box with the shape of a rhombic dodecahedron was
used, and a minimum distance of 12 Å from the solute was
guaranteed, resulting in5300 water molecules added. A single
Cl− counterion was also added to obtain a neutral system for the
sole HcTnI-C27 peptide. Simulations in the isobaric–isothermal
ensemble were carried out for 50 ns with a sampling time of 1 ps.
Details on the barostat/thermostat reference values and coupling
times, modeling of electrostatic and van der Waals interactions,
and other specifics on the annealing and equilibration proced-
ures used were as reported earlier (67, 68). The analysis of the
secondary structure of the peptides was performed with the
DSSP algorithm (69) and a sampling time of 10 ps.
Molecular docking
The structure of Tm was modeled on the basis of entry 1C1G
in the Protein Data Bank (70). Molecular docking was performed
using AutoDock Vina 1.1.2 (71) and with graphical interface
AutoDock Tools 1.5.6 (72). The system was described at atomic
detail with the exception of apolar hydrogens, which were sub-
sumed into the carbon atom they were bound to. The dockingexperiments were carried out using a “divide and conquer”
approach: the whole protein surface was mapped with a blind
search performed on smaller volumes having each a size 90 Å ×
90 Å × 55 Å and with a grid spacing of 1 Å. The HcTnI-C27
peptide possesses 122 rotatable dihedral angles, which is a
number too large for any current computational resource.
Therefore, we considered rotatable bonds only in the main chain
u and ψ angles of the peptide that did not show a stable sec-
ondary structure in the preceding MD simulation, leading to a
total of 44 rotatable bonds. The search was performed using an
exhaustiveness factor 16 times larger than the default value (73),
extending linearly the elapsed time while increasing exponen-
tially the probability of finding the most accurate energetic
minima (71). The maximum number of binding modes gener-
ated and the energy range obtained were always largely below
the maximum values allowed, i.e., 100 poses and 5 kcal/mol,
respectively. We verified that the binding scores obtained were
reproducible within 0.2 to 0.3 kcal/mol, due to the randomness
in the docking search algorithm.
Force-pCa measurements in skinned cardiac muscle strips
Permeabilized left ventricular papillary muscles from wild-
type and Tm180G (34) mice in C57B/L6 background at 3 to
4 months of age were prepared using cryosection for contrac-
tility studies (12, 74). Cardiac muscle strips 120 to 150 μm wide
and 35 μm thick were mounted between two aluminum T-clips
and transferred to a chamber of a thermo-controlled stage
(802D, Aurora Scientific) at 6 to 8 C in a relaxation buffer
(N,N-bis(2-hydroxyethyl)-2-aminoethane sulfonic acid 40 mM,
EGTA 10 mM, MgCl2 6.86 mM, ATP 5.96 mM, dithiothreitol
1 mM, creatine phosphate 33 mM, creatine kinase 200 U/ml,
K-propionate 3.28 mM, pH 7.0, plus protease inhibitor cock-
tail). The muscle preparation was connected to a force trans-
ducer (403A, Aurora Scientific) and a length controller
(322TSPC, Aurora Scientific). The buffer was then switched to
a skinning solution (relaxation buffer containing 1% Triton X-
100) for 20 min. After a wash with relaxation buffer, the per-
meabilized muscle strip was placed in pCa 9.0 buffer, and the
sarcomere length was measured through a digital camera
attached to the microscope and adjusted to 2.0 μm and 2.3 μm.
Calcium activated force was examined at pCa 6.5, 6.3, 6.0, 5.8,
5.5, 5.0, and 4.5 at 15 C. HcTnI-C27 or HcTnI-C27-H peptide
was then added at 20 μM and the force–pCa measurements
were repeated. The force–pCa curves were plotted and fitted
using Hill exponential equation for data analysis and statistical
analysis was performed using paired Student’s t-test.
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